American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
AVENUE THERAPEUTICS, INC.
$0.32
-3.39%
OTC: ATXI · 15-min delayed
$1.4MRevenue · FY2025
-$2.9MNet income
ATXIOTC
About AVENUE THERAPEUTICS, INC.
AVENUE THERAPEUTICS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2025
- $1.4M
- Net income
- -$2.9M
- Total assets
- $2.9M
Source: SEC EDGAR · updated Jun 8, 2026
Multi-year
Revenue & profit trend
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue Net income
FY 2024
Financial statements
Income statement
- Operating income
- -$11.3M
- Income tax
- $0
- Net income
- -$11.7M
- EPS (basic)
- $-15.79
Balance sheet
- Total assets
- $2.7M
- Current assets
- $2.7M
- Total liabilities
- $816.0K
- Current liabilities
- $816.0K
- Shareholders’ equity
- $1.9M
Cash flow
- Operating cash flow
- -$9.0M
- Investing cash flow
- -$811.0K
- Financing cash flow
- $9.8M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
OTC: ATXI
$0.32
-3.39%
15-minute delayed · data by Polygon.io
Past year · hover for prices
$0.15
$0.93
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
At a glance
- Reported a net loss of $2.9M in FY2025.
- Trading 66% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AVENUE THERAPEUTICS, INC..
Write a review
Newsroom
News about AVENUE THERAPEUTICS, INC.
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
Avenue Therapeutics Announces Reverse Stock Split
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
News & sentiment via Polygon.io
Explore
Browse all →
